The Impact Of COVID‐19 In The Management Of AL Amyloidosis And Immunoglobulin Deposition Disease: A

Given that, during the COVID‐19 pandemic, cases with AL amyloidosis and immunoglobulin deposition diseases (IDD) are at particular risk because they are immune-compromised from the plasma cell disorder and therapy associated immune defects, researchers characterize a local experience in caring for patients with AL amyloidosis and IDD. They assessed patient treatment as well as disease status since the start of the pandemic as declared by WHO on March 11, 2020. This study involved 96 patients with AL amyloidosis and IDD. Since the pandemic, patients’ treatments were stopped if they attained VGPR or better post induction. After attaining VGPR, treatment was stopped in 7 patients; others needed treatment modifications. Tests for COVID‐19 have been performed in 28 patients, and all tests have been negative. Based on the findings, it was concluded that it is mandatory to customize AL amyloidosis and IDD management on the clinical features, centers’ access to care under the pandemic restrictions, and the epidemiological aspects of the outbreak.

​

Source